Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

CD20-positive Non-Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China
Contact: Study coordinator (Keshu Zhou, MD) · drzhouks77@163.com
Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
Contact: Study coordinator (Chunyan Ji, MD) · jichunyan@sdu.edu.cn
Contact: Study coordinator (Fei Lu, MD) · lufeisdu2@163.com
Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Chunkang Chang, MD) · Changchunkang7010@aliyun.com · 86-13764643870
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Junyuan Qi, MD. PHD) · qijy@ihcams.ac.cn
Contact: Study coordinator (Mingyuan Sun, MD) · sunmingyuan@ihcams.ac.cn

Study leads

Junyuan Qi, MD, PHD
Principal Investigator
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences

View source on ClinicalTrials.gov